Patients receiving N-acetyl-l-cysteine (NAC) during hospitalisation for #SARSCoV2 pneumonia and discharged alive present a significantly shorter length of hospital stay compared to those who did not receive NAC https://bit.ly/3l1QsVo.
Faverio, P., Rebora, P., Rossi, E., Del Giudice, S., Montanelli, F., Garzillo, L., et al. (2022). Impact of N-acetyl-L-cysteine on SARS-CoV-2 pneumonia and its sequelae: results from a large cohort study. ERJ OPEN RESEARCH, 8(1) [10.1183/23120541.00542-2021].
Impact of N-acetyl-L-cysteine on SARS-CoV-2 pneumonia and its sequelae: results from a large cohort study
Faverio P.
;Rebora P.;Rossi E.;Del Giudice S.;Montanelli F.;Garzillo L.;Busnelli S.;Luppi F.;Valsecchi M. G.;Pesci A.
2022
Abstract
Patients receiving N-acetyl-l-cysteine (NAC) during hospitalisation for #SARSCoV2 pneumonia and discharged alive present a significantly shorter length of hospital stay compared to those who did not receive NAC https://bit.ly/3l1QsVo.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
10281-362524_VoR.pdf
accesso aperto
Tipologia di allegato:
Publisher’s Version (Version of Record, VoR)
Licenza:
Creative Commons
Dimensione
320.76 kB
Formato
Adobe PDF
|
320.76 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
